ITRM20010708A0 - Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. - Google Patents

Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.

Info

Publication number
ITRM20010708A0
ITRM20010708A0 IT2001RM000708A ITRM20010708A ITRM20010708A0 IT RM20010708 A0 ITRM20010708 A0 IT RM20010708A0 IT 2001RM000708 A IT2001RM000708 A IT 2001RM000708A IT RM20010708 A ITRM20010708 A IT RM20010708A IT RM20010708 A0 ITRM20010708 A0 IT RM20010708A0
Authority
IT
Italy
Prior art keywords
alcanoyl
carnitine
treatment
erectile dysfunction
erectile
Prior art date
Application number
IT2001RM000708A
Other languages
English (en)
Inventor
Aleardo Koverech
Andrea Lenzi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000708A priority Critical patent/ITRM20010708A1/it
Publication of ITRM20010708A0 publication Critical patent/ITRM20010708A0/it
Priority to DE60207442T priority patent/DE60207442T2/de
Priority to PCT/IT2002/000758 priority patent/WO2003047563A1/en
Priority to AT02804338T priority patent/ATE309800T1/de
Priority to DK02804338T priority patent/DK1450782T3/da
Priority to MXPA04005269A priority patent/MXPA04005269A/es
Priority to KR1020047007882A priority patent/KR100907938B1/ko
Priority to US10/497,498 priority patent/US20050080018A1/en
Priority to JP2003548819A priority patent/JP4370169B2/ja
Priority to EP02804338A priority patent/EP1450782B9/en
Priority to CA2465471A priority patent/CA2465471C/en
Priority to SI200230234T priority patent/SI1450782T1/sl
Priority to AU2002365847A priority patent/AU2002365847A1/en
Priority to PL371131A priority patent/PL211211B1/pl
Priority to HU0402062A priority patent/HU229214B1/hu
Priority to ES02804338T priority patent/ES2250749T3/es
Publication of ITRM20010708A1 publication Critical patent/ITRM20010708A1/it
Priority to US11/649,796 priority patent/US20070117762A1/en
Priority to US13/280,749 priority patent/US8343979B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IT2001RM000708A 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. ITRM20010708A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ES02804338T ES2250749T3 (es) 2001-12-04 2002-12-04 Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
JP2003548819A JP4370169B2 (ja) 2001-12-04 2002-12-04 勃起障害の治療のためのアルカノイルｌ−カルニチンの使用
CA2465471A CA2465471C (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
AT02804338T ATE309800T1 (de) 2001-12-04 2002-12-04 Verwendung einer kombinationszusammensetzung bestehend aus propionyl l-carnitin und weiteren wirkstoffen zur behandlung der erektilen dysfunktion
DK02804338T DK1450782T3 (da) 2001-12-04 2002-12-04 Anvendelse af et kombinationspræparat, der omfatter propionyl-L-carnitin og yderligere lægemidler, til behandling af erektil dysfunktion
MXPA04005269A MXPA04005269A (es) 2001-12-04 2002-12-04 Uso de alcanoil-l-carnitina para el tratamiento de disfuncion erectil.
KR1020047007882A KR100907938B1 (ko) 2001-12-04 2002-12-04 발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도
US10/497,498 US20050080018A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
DE60207442T DE60207442T2 (de) 2001-12-04 2002-12-04 VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
EP02804338A EP1450782B9 (en) 2001-12-04 2002-12-04 Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction
PCT/IT2002/000758 WO2003047563A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
SI200230234T SI1450782T1 (sl) 2001-12-04 2002-12-04 Uporaba kombinirane zmesi, ki vsebuje propionil L-karnitin in dodatna zdravila za zdravljenje erektivne disfunkcije
AU2002365847A AU2002365847A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction
PL371131A PL211211B1 (pl) 2001-12-04 2002-12-04 Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie
HU0402062A HU229214B1 (hu) 2001-12-04 2002-12-04 Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére
US11/649,796 US20070117762A1 (en) 2001-12-04 2007-01-05 Use of an alkanoyl L-carnitine for the treatment of the erectile dysfunction
US13/280,749 US8343979B2 (en) 2001-12-04 2011-10-25 Use of alkanoyl L-carnitine for the treatment of erectile dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.

Publications (2)

Publication Number Publication Date
ITRM20010708A0 true ITRM20010708A0 (it) 2001-12-04
ITRM20010708A1 ITRM20010708A1 (it) 2003-06-04

Family

ID=11455907

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.

Country Status (16)

Country Link
US (3) US20050080018A1 (it)
EP (1) EP1450782B9 (it)
JP (1) JP4370169B2 (it)
KR (1) KR100907938B1 (it)
AT (1) ATE309800T1 (it)
AU (1) AU2002365847A1 (it)
CA (1) CA2465471C (it)
DE (1) DE60207442T2 (it)
DK (1) DK1450782T3 (it)
ES (1) ES2250749T3 (it)
HU (1) HU229214B1 (it)
IT (1) ITRM20010708A1 (it)
MX (1) MXPA04005269A (it)
PL (1) PL211211B1 (it)
SI (1) SI1450782T1 (it)
WO (1) WO2003047563A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
DK2396005T3 (da) 2009-02-13 2026-02-09 Boehringer Ingelheim Int Sglt2 hæmmer til at forbedre glykæmisk kontrol
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
WO2016174155A1 (en) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
EP0793962B1 (en) * 1996-03-04 1999-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
IT1293539B1 (it) * 1997-07-16 1999-03-01 Sigma Tau Ind Farmaceuti Composizione nutritiva per soggetti in stato di debilitazione causato da stress
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6241471B1 (en) * 1999-08-26 2001-06-05 General Electric Co. Turbine bucket tip shroud reinforcement
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di

Also Published As

Publication number Publication date
KR100907938B1 (ko) 2009-07-16
MXPA04005269A (es) 2004-10-11
EP1450782B1 (en) 2005-11-16
EP1450782A1 (en) 2004-09-01
DE60207442D1 (de) 2005-12-22
DE60207442T2 (de) 2006-07-27
KR20050044594A (ko) 2005-05-12
ITRM20010708A1 (it) 2003-06-04
HU229214B1 (hu) 2013-09-30
JP2005511655A (ja) 2005-04-28
AU2002365847A1 (en) 2003-06-17
JP4370169B2 (ja) 2009-11-25
US8343979B2 (en) 2013-01-01
HUP0402062A2 (hu) 2005-02-28
ES2250749T3 (es) 2006-04-16
US20050080018A1 (en) 2005-04-14
DK1450782T3 (da) 2006-02-20
ATE309800T1 (de) 2005-12-15
WO2003047563A1 (en) 2003-06-12
SI1450782T1 (sl) 2006-02-28
PL211211B1 (pl) 2012-04-30
HUP0402062A3 (en) 2012-09-28
US20120041005A1 (en) 2012-02-16
EP1450782B9 (en) 2006-05-17
CA2465471A1 (en) 2003-06-12
PL371131A1 (en) 2005-06-13
CA2465471C (en) 2010-10-19
US20070117762A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
DE60222056D1 (de) Hebestuhl
DE60208385D1 (de) Antineoplasische kombinationspräparate
SI1446122T1 (sl) Uporaba flibanserina pri zdravljenju motenj seksualne zelje
MA27043A1 (fr) Azaindoles
ITMI20021972A1 (it) Dispositivo per uso medico.
ITMI20001705A0 (it) Procedimento per la denitrificazione delle acque
ITRM20010708A0 (it) Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
AU2001274649A1 (en) Topical preparation of alprostadil for the treatment of erectile dysfunction
DE60335328D1 (de) Spaltrohrpumpe
DE60209406D1 (de) Rohrpumpe
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
SE0301854L (sv) Antiigensättningsbehandling
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
ITRM20030178A1 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
ITMI20000050A0 (it) Procedimento per la preparazione della 5-carbossiftalide
NO20022101D0 (no) Peptider for behandling av erektil dysfunksjon
ITRM20020492A1 (it) Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
ITRM20010293A0 (it) Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
DE50214583D1 (de) Förderpumpe
ITMI20021205A0 (it) Uso di proteine per il trattamento della leishmaniosi
IT1319218B1 (it) Uso della mepartricina per il trattamento delle sindroni prostatichecroniche.
IT1320253B1 (it) Composizione farmaceutica per il trattamento della malaria.
IT1317752B1 (it) Procedimento per il trattamento di fanghi.
ITRM20030219A1 (it) Uso della liquerizia per la prevenzione e la cura di aids e sars.